Source: FierceBiotech Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune. The takeover gives Alexion control of SYNT001—a neonatal Fc receptor (FcRn) inhibitor in phase 1b/2a trials for patients with warm autoimmune hemolytic anemia (WAIHA) and pemphigus vulgaris (PV)…...
DOJ clears Cigna’s planned acquisition of Express Scripts
Source: FierceHealthcare The Department of Justice has given the green light to insurance giant Cigna Corp.'s planned $67 billion acquisition of pharmacy benefit manager Express Scripts. The move terminates the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, one of the conditions necessary to close the deal, officials said in…...
Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline
Source: Allergan DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will…...